What are the first‑line antibiotic options for an acute exacerbation of chronic obstructive pulmonary disease (COPD)?

First-Line Antibiotics for COPD Exacerbations

For acute COPD exacerbations with purulent sputum, prescribe amoxicillin or doxycycline as first-line therapy, with amoxicillin-clavulanate reserved for patients with very severe COPD or risk factors for resistant organisms.

When to Prescribe Antibiotics

Antibiotics are indicated when patients present with 1:

• Purulent sputum (most important clinical indicator)
• Severe exacerbations requiring hospitalization
• ICU admission 2

Do NOT prescribe antibiotics for patients with 3:

• Non-purulent sputum
• Mild exacerbations managed outpatient
• Normal C-reactive protein (CRP <20 mg/L) 4

Using CRP point-of-care testing can reduce antibiotic prescriptions by 20-50% without compromising outcomes 4.

Specific Antibiotic Choices

First-Line Options:

Amoxicillin 3:

• Most effective against common COPD pathogens (Haemophilus influenzae, Streptococcus pneumoniae)
• Preferred for mild-to-moderate exacerbations with purulent sputum
• Best benefit-to-risk ratio 4

Doxycycline 1, 4:

• Alternative first-line option
• 200 mg daily for 7 days demonstrated clinical cure benefit
• Favorable safety profile

Second-Line/Severe Disease:

Amoxicillin-clavulanate 5, 3:

• Reserve for very severe COPD
• Patients with risk factors for resistant organisms
• Previous antibiotic exposure

Fluoroquinolones (levofloxacin) 5:

• Alternative for severe exacerbations
• Consider local resistance patterns

Cephalosporins (cefditoren, cefpodoxime) 5, 2:

• Second/third-generation options for hospitalized patients
• Good lung tissue penetration

Critical Pitfalls to Avoid

1. Overuse in non-purulent exacerbations: Nearly half of hospitalized AECOPD patients without pneumonia receive unnecessary antibiotics with no outcome benefit 6

2. Ignoring severity stratification: Mild outpatient exacerbations without purulent sputum derive no benefit from antibiotics 3

3. Broad-spectrum overuse: Start narrow (amoxicillin/doxycycline) and escalate only based on severity, not reflexively 1

Evidence Quality Considerations

The 2021 AAFP guideline 1 provides the most recent systematic approach, recommending antibiotics with moderate quality evidence for clinical cure (OR 2.03,95% CI 1.47-2.80). However, this benefit applies primarily to patients with purulent sputum. The guideline explicitly states there is insufficient evidence to support preferential recommendation of specific antibiotics, so choice should be based on local resistance patterns and cost 1.

The 2017 ERS/ATS guideline 7 supports antibiotic use but emphasizes individualized assessment of purulence and severity.

Duration

Standard treatment duration is 7-10 days 1, 8, though shorter courses may be adequate for mild-to-moderate exacerbations responding well to therapy.